Marginal zone B cells acquire dendritic cell functions by trogocytosis

Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocy...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 375; no. 6581; p. eabf7470
Main Authors Schriek, Patrick, Ching, Alan C, Moily, Nagaraj S, Moffat, Jessica, Beattie, Lynette, Steiner, Thiago M, Hosking, Laine M, Thurman, Joshua M, Holers, V Michael, Ishido, Satoshi, Lahoud, Mireille H, Caminschi, Irina, Heath, William R, Mintern, Justine D, Villadangos, Jose A
Format Journal Article
LanguageEnglish
Published United States The American Association for the Advancement of Science 11.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimination through excessive trogocytosis. Capture of C3 by MHC II thus enables the transfer of cDC-like properties to MZ B cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0036-8075
1095-9203
DOI:10.1126/science.abf7470